Latest & greatest articles for gabapentin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on gabapentin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on gabapentin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for gabapentin

21. Randomized controlled trial of gabapentin as an adjunct to perioperative analgesia in total hip arthroplasty patients Full Text available with Trip Pro

Randomized controlled trial of gabapentin as an adjunct to perioperative analgesia in total hip arthroplasty patients Gabapentin was investigated as a single-dose adjunct to morphine for postoperative pain management. The primary objective was to determine if gabapentin given preoperatively and for two days postoperatively as part of multimodal analgesia would decrease postoperative morphine consumption in patients undergoing primary total hip arthroplasty (THA).The study group included 102 (...) patients aged 19-90 years who were undergoing primary THA in a single joint with no contraindications to the study medications, no chronic pain syndrome, and no chronic opioid use. Intervention group patients (n = 48) received gabapentin 600 mg po preoperatively and 200 mg postoperatively on the day of surgery. They were continued on gabapentin at 200 mg three times daily for two days. Control group patients (n = 54) received placebo in a similar fashion. Preoperatively, all patients were given 30 mg

2015 EvidenceUpdates Controlled trial quality: predicted high

22. Gabapentin and pregabalin: major adverse effects

Gabapentin and pregabalin: major adverse effects Prescrire IN ENGLISH - Spotlight ''Gabapentin and pregabalin: major adverse effects'', 1 November 2014 {1} {1} {1} | | > > > Gabapentin and pregabalin: major adverse effects Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Gabapentin and pregabalin: major adverse effects To reduce the consequences (...) of some severe adverse effects associated with gabapentin or pregabalin, it is advisable not to expose patients to them other than in situations where these drugs have proved to be highly effective. Gabapentin and pregabalin are used in certain epilepsies and for pain in neurological diseases. Pregabalin is also used to treat anxiety disorders. According to a review of French pharmacovigilance data published in 2013, between 1995 and 2009, 2415 adverse effects linked to gabapentin or pregabalin were

2014 Prescrire

23. Gabapentin Is as Effective as an Occlusal Appliance in Controlling Nighttime Masticatory EMG Activity

Gabapentin Is as Effective as an Occlusal Appliance in Controlling Nighttime Masticatory EMG Activity UTCAT2762, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Gabapentin Is as Effective as an Occlusal Appliance in Controlling Nighttime Masticatory EMG Activity Clinical Question In a patient with fixed orthodontic bands and nighttime parafunctional habits, is gabapentin as effective and safe as an oral appliance (...) in reducing levels of nighttime masticatory EMG activity? Clinical Bottom Line Gabapentin (200 or 300 mg at bedtime) is a good treatment option for reducing nighttime masticatory EMG activity when an occlusal appliance cannot be used; it also has a good safety profile. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1) Madani/2012 20 patients (stabilization splint group [n = 10] and gabapentin group [n = 10

2014 UTHSCSA Dental School CAT Library

24. Do venlafaxine and gabapentin control hot flashes in women with a history of breast cancer?

Do venlafaxine and gabapentin control hot flashes in women with a history of breast cancer? Do venlafaxine and gabapentin control hot flashes in women with a history of breast cancer? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Do venlafaxine and gabapentin control hot flashes in women with a history of breast (...) cancer? View/ Open Date 2012-12 Format Metadata Abstract Venlafaxine reduces hot flashes more than placebo in women with a history of breast cancer; adverse effects include dry mouth and constipation (strength of recommendation [SOR]: B, randomized clinical trials [RCTs] with heterogeneous outcomes). Gabapentin also reduces hot flashes more than placebo (SOR: B, a single RCT); adverse effects include dizziness and somnolence (SOR: C, standard reference). After having tried both medications, women

2014 Clinical Inquiries

25. Gabapentin

Gabapentin USE OF GABAPENTIN IN PREGNANCY 0344 892 0909 USE OF GABAPENTIN IN PREGNANCY (Date of issue: November 2014 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Gabapentin is an antiepileptic drug indicated as monotherapy (...) or adjunctive therapy in the treatment of partial seizures with or without secondary generalisation, and for the treatment of peripheral neuropathic pain. The available data concerning gabapentin exposure in pregnancy consist of relatively small prospective cohort studies (n=8) and ten case reports/series. Most data relates to gabapentin use in pregnancy for the treatment of maternal epilepsy. A few case reports/series describe use of gabapentin in the treatment of neuropathic pain or hyperemesis gravidarum

2014 UK Teratology Information Service

26. Narcotics, benzodiazepines, stimulants, and gabapentin: policies, initiatives, and practices across Canada, 2014

Narcotics, benzodiazepines, stimulants, and gabapentin: policies, initiatives, and practices across Canada, 2014 Narcotics, benzodiazepines, stimulants, and gabapentin: policies, initiatives, and practices across Canada, 2014 Narcotics, benzodiazepines, stimulants, and gabapentin: policies, initiatives, and practices across Canada, 2014 CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation CADTH. Narcotics, benzodiazepines, stimulants, and gabapentin: policies, initiatives, and practices across Canada, 2014. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Environmental Scans; issue 45. 2014 Authors' conclusions The survey of Canada's publicly funded drug plans, colleges of physicians and surgeons, and colleges of pharmacists shows that jurisdictions have established multiple avenues to address the issue

2014 Health Technology Assessment (HTA) Database.

27. Gabapentin for adults with neuropathic pain: a review of the clinical evidence and guidelines

Gabapentin for adults with neuropathic pain: a review of the clinical evidence and guidelines Gabapentin for adults with neuropathic pain: a review of the clinical evidence and guidelines Gabapentin for adults with neuropathic pain: a review of the clinical evidence and guidelines CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation (...) CADTH. Gabapentin for adults with neuropathic pain: a review of the clinical evidence and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response. 2014 Authors' conclusions Indirect evidence suggests similar short-term pain relief with gabapentin compared with pregabalin, tricyclic antidepressants and serotonin norepinephrine reuptake inhibitors in patients with painful diabetic neuropathy, postherpetic neuralgia and fibromyalgia. There is lower quality

2014 Health Technology Assessment (HTA) Database.

28. Gabapentin Treatment for Alcohol Dependence: A Randomized Clinical Trial Full Text available with Trip Pro

Gabapentin Treatment for Alcohol Dependence: A Randomized Clinical Trial Approved medications for alcohol dependence are prescribed for less than 9% of US alcoholics.To determine if gabapentin, a widely prescribed generic calcium channel/γ-aminobutyric acid-modulating medication, increases rates of sustained abstinence and no heavy drinking and decreases alcohol-related insomnia, dysphoria, and craving, in a dose-dependent manner.A 12-week, double-blind, placebo-controlled, randomized dose (...) -ranging trial of 150 men and women older than 18 years with current alcohol dependence, conducted from 2004 through 2010 at a single-site, outpatient clinical research facility adjoining a general medical hospital.Oral gabapentin (dosages of 0 [placebo], 900 mg, or 1800 mg/d) and concomitant manual-guided counseling.Rates of complete abstinence and no heavy drinking (coprimary) and changes in mood, sleep, and craving (secondary) over the 12-week study. RESULTS Gabapentin significantly improved

2013 EvidenceUpdates Controlled trial quality: predicted high

29. Intrathecal gabapentin to treat chronic intractable noncancer pain Full Text available with Trip Pro

Intrathecal gabapentin to treat chronic intractable noncancer pain Oral gabapentin is approved as an anticonvulsant medication and to treat postherpetic neuralgia. Its nonopioid properties and presumed spinal site of analgesic action made the study on intrathecal gabapentin attractive to establish the minimum effective dose for a later, pivotal trial.The authors examined the safety and efficacy of intrathecal gabapentin in a randomized, blinded, placebo-controlled, multicenter trial (...) in a heterogeneous cohort of candidates with chronic pain for intrathecal drug therapy.Patients (N = 170) were randomized to receive continuous intrathecal gabapentin (0 [placebo], 1, 6, or 30 mg/day) during 22 days of blinded treatment after implantation of a permanent drug delivery system. The highest dose, 30 mg/day, was selected to maintain a safety margin below the 100-mg/day dose that was explored in a phase 1 study. The authors found no statistically significant difference in the primary outcome measure

2013 EvidenceUpdates Controlled trial quality: uncertain

30. A single preoperative dose of gabapentin does not improve postcesarean delivery pain management: a randomized, double-blind, placebo-controlled dose-finding trial (Abstract)

A single preoperative dose of gabapentin does not improve postcesarean delivery pain management: a randomized, double-blind, placebo-controlled dose-finding trial A single preoperative dose of 600 mg gabapentin, combined with multimodal analgesia, has previously been shown to reduce postcesarean pain and improve maternal satisfaction but was associated with increased maternal sedation. We hypothesized that a lower dose of gabapentin may be effective with less sedation.We conducted a doubleblind (...) , randomized, placebo-controlled study. Women undergoing elective cesarean delivery were randomized into 3 groups to receive 300 or 600 mg oral gabapentin, or placebo, 1 hour before surgery. Temporal summation (TS) testing was performed at the time of study drug administration, and a visual analog scale (0 to 100 mm) difference ≥10 mm between the 1st and 10th stimuli was considered TS+. Spinal anesthesia and postoperative analgesia were instituted, including intrathecal fentanyl and morphine, oral

2012 EvidenceUpdates Controlled trial quality: predicted high

31. Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. (Abstract)

Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. Refractory chronic cough causes substantial symptoms and quality-of-life impairment. Similarities between central reflex sensitisation in refractory chronic cough and neuropathic pain suggest that neuromodulators such as gabapentin might be effective for refractory chronic cough. We established the efficacy of gabapentin in patients with refractory chronic cough.This randomised, double-blind, placebo (...) -controlled trial was undertaken at an outpatient clinic in Australia. Adults with refractory chronic cough (>8 weeks' duration) without active respiratory disease or infection were randomly assigned to receive gabapentin (maximum tolerable daily dose of 1800 mg) or matching placebo for 10 weeks. Block randomisation was done with randomisation generator software, stratified by sex. Patients and investigators were masked to assigned treatment. The primary endpoint was change in cough-specific quality

2012 Lancet Controlled trial quality: predicted high

32. Limited evidence does not support use of gabapentin as stand-alone therapy for acute postoperative pain

Limited evidence does not support use of gabapentin as stand-alone therapy for acute postoperative pain Limited evidence does not support use of gabapentin as stand-alone therapy for acute postoperative pain ADA Websites Access news, member benefits and ADA policy Attend ADA's premier event Access cutting-edge continuing education courses Find evidence to support your clinical decisions Access member-only practice content Investing in better oral health for all. Together. Take advantage (...) evidence does not support use of gabapentin as stand-alone therapy for acute postoperative pain Arthur Jeske DMD, PhD; James Zahrowski DMD, MS, PharmD . Overview Systematic Review Conclusion Gabapentin (250 mg) is statistically superior to placebo for treating established acute postoperative pain. However, to achieve at least 50 percent pain relief over six hours, the number of patients needed to treat was 11, which suggests gabapentin has limited clinical value and is inferior to common analgesics

2011 ADA Center for Evidence-Based Dentistry

33. Limited evidence does not support use of gabapentin as stand-alone therapy for acute postoperative pain

Limited evidence does not support use of gabapentin as stand-alone therapy for acute postoperative pain Limited evidence does not support use of gabapentin as stand-alone therapy for acute postoperative pain ADA Websites Access news, member benefits and ADA policy Attend ADA's premier event Access cutting-edge continuing education courses Find evidence to support your clinical decisions Access member-only practice content Investing in better oral health for all. Together. Take advantage (...) evidence does not support use of gabapentin as stand-alone therapy for acute postoperative pain Arthur Jeske DMD, PhD; James Zahrowski DMD, MS, PharmD . Overview Systematic Review Conclusion Gabapentin (250 mg) is statistically superior to placebo for treating established acute postoperative pain. However, to achieve at least 50 percent pain relief over six hours, the number of patients needed to treat was 11, which suggests gabapentin has limited clinical value and is inferior to common analgesics

2011 ADA Center for Evidence-Based Dentistry

34. Limited evidence does not support use of gabapentin as stand-alone therapy for acute postoperative pain

Limited evidence does not support use of gabapentin as stand-alone therapy for acute postoperative pain Limited evidence does not support use of gabapentin as stand-alone therapy for acute postoperative pain ADA Websites Access news, member benefits and ADA policy Attend ADA's premier event Access cutting-edge continuing education courses Find evidence to support your clinical decisions Access member-only practice content Investing in better oral health for all. Together. Take advantage (...) evidence does not support use of gabapentin as stand-alone therapy for acute postoperative pain Arthur Jeske DMD, PhD; James Zahrowski DMD, MS, PharmD . Overview Systematic Review Conclusion Gabapentin (250 mg) is statistically superior to placebo for treating established acute postoperative pain. However, to achieve at least 50 percent pain relief over six hours, the number of patients needed to treat was 11, which suggests gabapentin has limited clinical value and is inferior to common analgesics

2011 ADA Center for Evidence-Based Dentistry

35. WITHDRAWN: Gabapentin for acute and chronic pain. Full Text available with Trip Pro

WITHDRAWN: Gabapentin for acute and chronic pain. February 2009: The authors are aware of unpublished trial data for Gabapentin which could affect the results of this review. This information together with that from trials published since 2005, will be considered when this review is updated in 2009.Anticonvulsant drugs have been used in the management of pain since the 1960s. The clinical impression is that they are useful for chronic neuropathic pain, especially when the pain is lancinating (...) or burning.To evaluate the analgesic effectiveness and adverse effects of gabapentin for pain management in clinical practice.Randomised trials of gabapentin in acute, chronic or cancer pain were identified by MEDLINE (1966 to Nov 2004), EMBASE (1994 to Nov 2004), SIGLE (1980 to Jan 2004) and the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library, Issue 4, 2004). Additional studies were identified from the reference list of the retrieved papers, and by contacting investigators

2011 Cochrane

36. Horizant (gabapentin enacarbil) Extended-Release Tablets

Horizant (gabapentin enacarbil) Extended-Release Tablets Drug Approval Package: Horizant (gabapentin enacarbil) NDA #022399 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Horizant (gabapentin enacarbil) Extended-Release Tablets Company: GlaxoSmithKline Application No.: 022399 Approval Date: 4/06/2011 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

2011 FDA - Drug Approval Package

37. Cochrane systematic review: Clonidine, SSRIs, SNRIs and gabapentin reduce hot flushes in women with a history of breast cancer; relaxation therapy may have a mild effect in the short term

Cochrane systematic review: Clonidine, SSRIs, SNRIs and gabapentin reduce hot flushes in women with a history of breast cancer; relaxation therapy may have a mild effect in the short term Clonidine, SSRIs, SNRIs and gabapentin reduce hot flushes in women with a history of breast cancer; relaxation therapy may have a mild effect in the short term | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings (...) via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Clonidine, SSRIs, SNRIs and gabapentin

2011 Evidence-Based Nursing

38. Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: findings from a cost-consequences analysis in a nested case-control study

Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: findings from a cost-consequences analysis in a nested case-control study Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: findings from a cost-consequences analysis in a nested case-control study Pregabalin and gabapentin in matched patients with peripheral neuropathic pain (...) was to assess the costs and benefits of pregabalin and gabapentin, for the treatment of adults with peripheral neuropathic pain, in routine medical practice. The authors concluded that pregabalin seemed to reduce the mean weekly intensity of pain more than gabapentin, with no significant difference in costs. The reporting and methods were satisfactory. The authors' conclusion appears to be appropriate, but highly uncertain. Type of economic evaluation Cost-effectiveness analysis, cost-utility analysis Study

2010 NHS Economic Evaluation Database.

39. Gabapentin and pregabalin in the treatment of fibromyalgia: a systematic review and a meta-analysis

Gabapentin and pregabalin in the treatment of fibromyalgia: a systematic review and a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

40. New users of the anticonvulsants gabapentin, lamotrigine, oxcarbazepine or tiagabine are at increased risk of suicidal acts compared with new users of topiramate

New users of the anticonvulsants gabapentin, lamotrigine, oxcarbazepine or tiagabine are at increased risk of suicidal acts compared with new users of topiramate New users of the anticonvulsants gabapentin, lamotrigine, oxcarbazepine or tiagabine are at increased risk of suicidal acts compared with new users of topiramate | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser (...) at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here New users of the anticonvulsants gabapentin, lamotrigine

2010 Evidence-Based Mental Health